Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Thu, Mar 20, 2025
[Archive]
Volume 15, Issue 4 (Autumn 2024)
Caspian J Intern Med 2024, 15(4): 706-712 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Alizadeh Sadighi S, Rostami N, Tohidi M, Mashayekhi M. Insulin-like growth factor (IGF) levels in pre-treatment plasma identifying breast cancer: A case control study. Caspian J Intern Med 2024; 15 (4) :706-712
URL: http://caspjim.com/article-1-3960-en.html
URL: http://caspjim.com/article-1-3960-en.html
Department of internal medicine, clinical research development center at modarres hospital, shahid beheshti university of medical science, Tehran, iran , s.alzsadighi@gmail.com
Abstract: (675 Views)
Background: Diabetes (primarily type 2) is linked to a higher risk of breast cancer. Insulin-like growth factor (IGF) is one of the most important factors that affects mitosis and thus inhibits apoptosis. The purpose of this study was to compare the pre-treatment insulin-like growth factor (IGF) levels in breast cancer against normal population.
Methods: In this case-control study, 60 patients with breast cancer and 60 healthy controls were enrolled in 2017 and 2018 at Tehran's Shahid-Modarres Hospital. In this study, the blood sugar of the patients was examined before entering the study, and the age of the patients was also within the age limit of 18 to 70 years. They were studied to determine the relationship between insulin-like growth factor (ELISA method) and breast cancer.
Results: Both groups have similar IGF-1 levels (Ctrl and Case) (P= 0.188). But, IGF-2 levels were significantly higher in breast cancer patients (373.4 vs. 317.3 ng/ml), (P=0.0001).
Conclusion: According to our study, IGF-2 may serve as a prognostic biomarker and potential therapeutic target for breast cancer. However, further investigation is needed to validate this claim.
Methods: In this case-control study, 60 patients with breast cancer and 60 healthy controls were enrolled in 2017 and 2018 at Tehran's Shahid-Modarres Hospital. In this study, the blood sugar of the patients was examined before entering the study, and the age of the patients was also within the age limit of 18 to 70 years. They were studied to determine the relationship between insulin-like growth factor (ELISA method) and breast cancer.
Results: Both groups have similar IGF-1 levels (Ctrl and Case) (P= 0.188). But, IGF-2 levels were significantly higher in breast cancer patients (373.4 vs. 317.3 ng/ml), (P=0.0001).
Conclusion: According to our study, IGF-2 may serve as a prognostic biomarker and potential therapeutic target for breast cancer. However, further investigation is needed to validate this claim.
Type of Study: Short Communication |
Subject:
Oncology
Received: 2023/05/17 | Accepted: 2023/12/5 | Published: 2024/08/8
Received: 2023/05/17 | Accepted: 2023/12/5 | Published: 2024/08/8
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
